OTCPK:BRRZ.Y

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Total Brain Limited develops and sells brain health products in the United States.


Snowflake Analysis

High growth potential with adequate balance sheet.

Share Price & News

How has Total Brain's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BRRZ.Y has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

BRRZ.Y

1.6%

US Healthcare

3.0%

US Market


1 Year Return

n/a

BRRZ.Y

15.3%

US Healthcare

15.8%

US Market

Return vs Industry: Insufficient data to determine how BRRZ.Y performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how BRRZ.Y performed against the US Market.


Shareholder returns

BRRZ.YIndustryMarket
7 Day0%1.6%3.0%
30 Dayn/a4.4%6.0%
90 Dayn/a6.7%16.4%
1 Yearn/a16.8%15.3%18.4%15.8%
3 Yearn/a34.9%28.9%44.8%35.4%
5 Yearn/a46.8%36.5%75.7%56.7%

Price Volatility Vs. Market

How volatile is Total Brain's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Total Brain undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BRRZ.Y ($3) is trading below our estimate of fair value ($20.32)

Significantly Below Fair Value: BRRZ.Y is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BRRZ.Y is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: BRRZ.Y is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BRRZ.Y's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BRRZ.Y is good value based on its PB Ratio (1.7x) compared to the US Healthcare industry average (3.1x).


Next Steps

Future Growth

How is Total Brain forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

95.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BRRZ.Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: BRRZ.Y is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BRRZ.Y's is expected to become profitable in the next 3 years.

Revenue vs Market: BRRZ.Y's revenue (67.3% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: BRRZ.Y's revenue (67.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BRRZ.Y's Return on Equity is forecast to be low in 3 years time (3.2%).


Next Steps

Past Performance

How has Total Brain performed over the past 5 years?

-26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BRRZ.Y is currently unprofitable.

Growing Profit Margin: BRRZ.Y is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BRRZ.Y is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare BRRZ.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BRRZ.Y is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (16.3%).


Return on Equity

High ROE: BRRZ.Y has a negative Return on Equity (-32.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is Total Brain's financial position?


Financial Position Analysis

Short Term Liabilities: BRRZ.Y's short term assets (A$10.4M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: BRRZ.Y's short term assets (A$10.4M) exceed its long term liabilities (A$102.5K).


Debt to Equity History and Analysis

Debt Level: BRRZ.Y is debt free.

Reducing Debt: BRRZ.Y has no debt compared to 5 years ago when its debt to equity ratio was 42.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BRRZ.Y has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BRRZ.Y has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Total Brain current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BRRZ.Y's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BRRZ.Y's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BRRZ.Y's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BRRZ.Y's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BRRZ.Y's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Louis Gagnon

3.25yrs

Tenure

AU$708,253

Compensation

Mr. Louis Gagnon has been Chief Executive Officer of Total Brain Limited (formerly known as Brain Resource Limited) since May 22, 2017 and has been its Managing Director since December 22, 2017. Mr. Gagnon ...


CEO Compensation Analysis

Compensation vs Market: Louis's total compensation ($USD511.01K) is about average for companies of similar size in the US market ($USD606.98K).

Compensation vs Earnings: Louis's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Evian Gordon
Founder & Executive Chairmanno dataAU$349.47k1.2%
A$ 408.6k
Louis Gagnon
MD, CEO & Director3.25yrsAU$708.25k0.38%
A$ 130.5k
Emil Vasilev
Director of Finance & Operations3.25yrsAU$284.02k0.065%
A$ 22.0k
Matthew Mund
Chief Operating Officer3yrsAU$482.76k0.91%
A$ 310.3k
Marcel Legrand
Head of Revenue & Corporate Development3yrsno datano data
Matt Resteghini
Chief Marketing Officer2.5yrsno datano data
Simon Poidevin
President of Australia & New Zealand0.42yrno datano data
Phillip Hains
Joint Company Secretary2.08yrsno datano data
Nathan Jong
Joint Company Secretary0.75yrno datano data

2.8yrs

Average Tenure

Experienced Management: BRRZ.Y's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Evian Gordon
Founder & Executive Chairmanno dataAU$349.47k1.2%
A$ 408.6k
Louis Gagnon
MD, CEO & Director3.25yrsAU$708.25k0.38%
A$ 130.5k
Matthew Morgan
Independent Non-Executive Director4.42yrsAU$106.07k0.41%
A$ 139.6k
David Daglio
Non-Executive Director0.58yrno data6.42%
A$ 2.2m
David Torrible
Non-Executive Director1.17yrsAU$5.02k5.59%
A$ 1.9m

1.9yrs

Average Tenure

Experienced Board: BRRZ.Y's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.3%.


Top Shareholders

Company Information

Total Brain Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Total Brain Limited
  • Ticker: BRRZ.Y
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$47.112m
  • Listing Market Cap: AU$33.991m
  • Shares outstanding: 108.30m
  • Website: https://www.totalbrain.com

Number of Employees


Location

  • Total Brain Limited
  • 268 Bush Street
  • Suite 2633
  • San Francisco
  • California
  • 94104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TTBL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDAug 2001
TTBASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2001
BRRZ.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDApr 2011

Biography

Total Brain Limited develops and sells brain health products in the United States. It offers Total Brain, a neuroscience-based mental health and fitness platform. Total Brain Limited has a partnership with ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 00:41
End of Day Share Price2020/07/27 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.